
[Federal Register Volume 78, Number 221 (Friday, November 15, 2013)]
[Notices]
[Pages 68854-68855]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-27359]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2013-N-1038]


Over-the-Counter Ophthalmic Drug Products--Emergency Use Eyewash 
Products; Rescheduling of Public Hearing

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; rescheduling of public hearing.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is rescheduling a 
December 4, 2013, public hearing to obtain information on the 
formulation, manufacturing, and labeling of currently marketed over-
the-counter (OTC) emergency use eyewash products, announced in the 
Federal Register of Wednesday, September 18, 2013. Based on a request 
received by the Agency, we are rescheduling the public hearing to March 
7, 2014, and updating the related procedural dates that appeared in the 
September 18, 2013, notice.

DATES: The public hearing will be held on March 7, 2014, from 9 a.m. to 
5 p.m. Submit electronic or written requests to make oral presentations 
and comments by February 14, 2014. If you wish to attend the hearing or 
make an oral presentation during the hearing, you must register by 
submitting an electronic request to CDEREYEWASHMEETING@fda.hhs.gov by 
close of business on February 14, 2014. For those unable to attend in 
person, FDA will provide a Webcast to the meeting; additional 
information about the Webcast location will be posted on the Web page 
at http://www.fda.gov/Drugs/NewsEvents/ucm356526.htm prior to March 7, 
2014. Electronic or written comments will be accepted after the hearing 
until June 6, 2014.

FOR FURTHER INFORMATION CONTACT: Mary C. Gross, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Silver Spring, MD 20903, 301-796-3519, FAX: 301-847-
8753, mary.gross@fda.hhs.gov; or Elaine Abraham, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire

[[Page 68855]]

Ave., Silver Spring, MD 20903, 301-796-0843, FAX: 301-796-9899, 
elaine.abraham@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In the Federal Register of September 18, 
2013 (78 FR 57397), FDA announced that it would hold a public hearing 
on December 4, 2013, to obtain information on the formulation, 
manufacturing, and labeling of currently marketed OTC emergency use 
eyewash products. Based on a request received by the Agency, we are 
rescheduling the public hearing to March 7, 2014. Because we are 
rescheduling the hearing, we are also rescheduling the procedural dates 
(see DATES) that appeared in the September 18, 2013, notice. For 
additional information about the purpose and scope of the hearing, see 
the September 18, 2013, notice available on FDA's Web site at http://www.fda.gov/Drugs/NewsEvents/ucm356526.htm.

    Dated: November 8, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-27359 Filed 11-14-13; 8:45 am]
BILLING CODE 4160-01-P


